NCT05529069View on ClinicalTrials.gov

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

April 28, 2027

Study Completion Date

April 28, 2027

Conditions
Mantle Cell LymphomaNon Hodgkin LymphomaHematologic Malignancy
Interventions
DRUG

Pirtobrutinib

Given by PO

DRUG

Venetoclax

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Loxo Oncology
All Listed Sponsors
collaborator

Loxo Oncology

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT05529069 - Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | Biotech Hunter | Biotech Hunter